Opioid Induced Constipation News and Research

RSS
RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

P2 COVID-19 study shows no material safety differences between opaganib and control arms

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

RedHill Biopharma announces promising preliminary results from opaganib study

RedHill Biopharma announces promising preliminary results from opaganib study

Opioid maker funds efforts to fight addiction: Is it ‘blood money’ or charity?

Opioid maker funds efforts to fight addiction: Is it ‘blood money’ or charity?

Naldemedine significantly improves opioid-induced constipation in patients with chronic non-cancer pain

Naldemedine significantly improves opioid-induced constipation in patients with chronic non-cancer pain

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation